earnings
confidence high
sentiment positive
materiality 0.75
Arcadia Biosciences Q1 net income $2.6M; Zola sales up 90%; Roosevelt deal amended to 90/10 split
Arcadia Biosciences, Inc.
2025-Q1 EPS
reported $1.90
vs consensus -$1.00
▲ beat
(+290.1%)
- Q1 2025 net income $2.6M ($1.90/share) vs net loss of $2.4M ($1.78 loss) in Q1 2024.
- Revenue $1.2M (+22% YoY) driven by Zola coconut water sales up 90% and distribution up 70%.
- Sold patent portfolios for $750K, eliminating $1M in liabilities; operating expenses near 10-year low.
- Amended Roosevelt merger: fixed equity split 90% to Roosevelt partners, 10% to Arcadia stockholders; expected close late summer.
- Cash and cash equivalents $3.16M, down from $4.24M at Dec 31, 2024.